Table 1. Ongoing comparative clinical trials evaluating ruxolitinib in adults with essential thrombocythemia.

Clinicaltrials.gov identifier	Other name	Phase	Sponsor	Comparator	Major eligibility criteria
NCT03123588	RESET-272	2	Incyte Corporation	Anagrelide	HU resistance or intolerance;[3] platelets >650 × 109/L and leukocytes >11 × 109/L at screening
NCT02962388	RUXBETA	2/3	French Innovative Leukemia Organization	Anagrelide or interferon alfa (can be pegylated)	Patients with high risk ET and HU resistance or intolerance[3]
NCT02577926	Ruxo-BEAT	3	RWTH Aachen University	Best available therapy	Treatment-naïve or previously treated patients who are >60 or have platelets >1500 × 109/L, or h/o prior thromboembolism or ET-related severe hemorrhage

Abbreviations: ET, essential thrombocythemia; HU, hydroxyurea.